(NASDAQ: INAB) In8bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.57%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.48%.
In8bio's earnings in 2026 is -$18,667,000.On average, 5 Wall Street analysts forecast INAB's earnings for 2026 to be -$11,195,180, with the lowest INAB earnings forecast at -$14,395,211, and the highest INAB earnings forecast at -$9,212,659. On average, 5 Wall Street analysts forecast INAB's earnings for 2027 to be -$9,552,773, with the lowest INAB earnings forecast at -$11,979,907, and the highest INAB earnings forecast at -$6,624,833.
In 2028, INAB is forecast to generate -$3,921,665 in earnings, with the lowest earnings forecast at -$5,313,668 and the highest earnings forecast at -$2,380,799.